Proteros enters into a research agreement for structure based lead generation
Proteros biostructures GmbH (Proteros) announced that it has entered into an agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), under which Proteros will perform research to discover small molecule lead compounds against a specific target for delivery to J&JPRD. Under the agreement, Proteros will deploy its integrated lead discovery approach that interlinks structural biology, screening of a tailor-made in-house compound and fragment library, compound profiling, and medicinal chemistry activities aimed at rapid fragment evolution and lead finding.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.